Boehringer Ingelheim enters collaboration on hearing loss treatment for up to USD 100m

Biotech firm Autigen has inked a research collaboration and license agreement with Boehringer Ingelheim to discover and develop treatments for hearing loss.

Photo: Joachim Adrian/Politiken/Ritzau Scanpix

by albert rønning-andersson, translated by daniel pedersen

German Boehringer Ingelheim and US-based biotech firm Autigen are partnering up to discover and develop potential hearing loss treatments, the company has announced in a press release on Wednesday, as reported by industry media Fierce Biotech.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles

Receive our daily newsletters

Access our app

Get full access for you and your coworkers

Start a free company trial today

Sonova enters strategic alliance with French biotech company to treat hearing loss
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

Joe Biden demands lower prices for Wegovy and Ozempic

This is not the first time Joe Biden has criticized the high price of medicine in the US.

Novo Nordisk CEO to testify before senate committee in September

Novo on US senate subpoena vote: "We have repeatedly told them that Lars Fruergaard would be happy to testify"

For subscribers

Henrik Blou, CEO, Gubra | Foto: Thomas Muus / Gubra / Pr

Pharma & biotech

Gubra crowned Danish biotech firm of the year: "We have focused on the exciting research"

For subscribers

Foto: Lindsey Wasson/Reuters/Ritzau Scanpix

Pharma & biotech

Bill & Melinda Gates Foundation to support development of Snipr asset

For subscribers

Pharma & biotech

New law protects subsidies for obesity drugs when transitioning to Medicare

For subscribers

Pharma & biotech

Astrazeneca granted accelerated assessment of Covid candidate

For subscribers

Hearing health

No legal barrier to foundation employing fired Demant boss — just ethical considerations

For subscribers

Foto: China Stringer Network/Reuters/Ritzau Scanpix

Boehringer Ingelheim starts early-stage testing of weight loss candidate

The study is the second clinical study in the collaboration between Gubra and Boehringer Ingelheim.

Eli Lilly sees big potential in severe obesity candidates

The US-based pharmaceutical firm has two obesity candidates in its pipeline.

Novo Nordisk: Patients are more important than the climate

The pharmaceutical giant’s greenhouse gas emissions grew 53% last year. According to the company’s head of sustainability, the increase is due to ongoing production expansions.

For subscribers

Bavarian Nordic converts credit facility to green loan

The terms of the loan are now linked to Bavarian Nordic’s sustainability strategy.

Former Demant Executive Vice President Arne Boye Nielsen was found responsible for creating an "unsafe psychological work environment" in an internal legal investigation. | Foto: Demant / Pr

Demant Foundation continues to work with ousted Demant executive

While the findings of a legal investigation were so serious that a Demant executive was fired, the majority owner of the hearing aid company subsequently elected him to several boards.

For subscribers

CHMP recommends ten new medicines in June

Among other things, the first mRNA vaccine not targeting COVID-19 has been recommended for approval.

For subscribers

Novo Nordisk: Patients are more important than the climate

The pharmaceutical giant’s greenhouse gas emissions grew 53% last year. According to the company’s head of sustainability, the increase is due to ongoing production expansions.

For subscribers

Pharma & biotech

Joe Biden demands lower prices for Wegovy and Ozempic

This is not the first time Joe Biden has criticized the high price of medicine in the US.

For subscribers

Pharma & biotech

Boehringer Ingelheim starts early-stage testing of weight loss candidate

The study is the second clinical study in the collaboration between Gubra and Boehringer Ingelheim.

Pharma & biotech

Eli Lilly sees big potential in severe obesity candidates

The US-based pharmaceutical firm has two obesity candidates in its pipeline.

Hearing health

No legal barrier to foundation employing fired Demant boss — just ethical considerations

The William Demant Foundation has raised eyebrows by hiring a former CEO fired from Demant, but there are virtually no legal rules for the large corporate foundations, several lawyers highlight.

For subscribers